A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. (Q33419633)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

main subject

phase II clinical trial

0 references

angiogenesis inhibitor

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Alexander I Aspinall

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Neesha Dhani

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Glen Lo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Tae Kyoung Kim

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Lisa W Le

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Anne M Horgan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Kelly W Burak

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Eric Chen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Mehrdad Sinaei

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Patrik Rogalla

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Oliver F Bathe

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jennifer J Knox

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

6 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

121

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

1620-1627

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Vascular changes in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

inferred from DOI database lookup

7 January 2021

based on heuristic

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

inferred from DOI database lookup

7 January 2021

based on heuristic

Effects of vascular endothelial growth factor on hemodynamics and cardiac performance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29227

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.29227

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25565269%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference